Actively Recruiting
Evaluation of Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of CS5007, a Novel EGFR and HER3 Antibody-Drug Conjugate, in Adults With Advanced Solid Tumors
Led by CStone Pharmaceuticals · Updated on 2026-08-14
310
Participants Needed
7
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating CS5007, a new EGFR and HER3 bispecific antibody-drug conjugate, in adults with advanced solid tumors that cannot be surgically removed. This first-in-human, open-label Phase I trial is designed to assess the safety, tolerability, how the drug moves through the body, and initial anti-tumor effects. The study includes two parts a dose escalation phase to find safe dose levels and a dose expansion phase to further assess the drug at recommended doses. Participants will receive CS5007 through intravenous infusion on Day 1 of repeated 21-day cycles. During the dose escalation phase, doses will gradually increase to determine the maximum tolerated dose and recommended Phase II dose. In the dose expansion phase, participants will receive the recommended doses based on earlier results. Treatment will continue with regular cycles while monitoring effects and side effects. Throughout the study, participants will undergo scheduled visits including laboratory tests, tumor assessments, and safety monitoring for up to about two years. Researchers will measure outcomes such as maximum tolerated dose, adverse events, tumor response by RECIST criteria, and pharmacokinetic parameters of CS5007. Participants are expected to comply with study procedures and receive ongoing evaluation to monitor the drugs effects and safety during this time.
CONDITIONS
Brief Title
A Phase I Study of CS5007 in Participants With Advanced Solid Tumors
Research Team
S
Sean Yao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here